Why it matters: patients with EGFR exon 20 mutations saw progression-free survival jump to 14.5 months vs 8.5 months. That’s nearly double. Sure, side effects are higher; but manageable with careful monitoring. This isn’t just another trial result. It’s a potential game-changer for a subgroup that’s had few good options. And here’s the twist: the same drug is already under review for patients who failed chemo first. If both approvals come through, this could become the go-to frontline and second-line treatment. For oncologists and patients watching closely; this could reshape NSCLC care by mid-2027.